Vabiotech, a company focused on production of vaccines, has licensed Inviragen's proprietary Japanese encephalitis (JE) technology to produce a cell-derived vaccine.
Subscribe to our email newsletter
Under the license, VABIOTECH is expected to develop and commercialize JE vaccine in Vietnam, Cambodia and Myanmar.
In addition, VABIOTECH will provide certain development-based milestone payments to Inviragen.
Vabiotech director general Nguyen Thu Van said in partnership with the Ministry of Health, the company has made great strides to control the spread of JE infection in Vietnam.
"We look forward to incorporating this vaccine technology from Inviragen into our JE program," Van added.